|
In advance of crucial meeting, Biogen’s Alzheimer’s drug wins praise from FDA
|
|
Biogen’s closely watched experimental drug for Alzheimer’s disease got a boost Wednesday after reviewers for the Food and Drug Administration said it appeared to be safe and effective.
The assessments propelled the Cambridge biotech’s stock up by more than 40 percent, two days before an FDA advisory committee is expected to meet on whether to recommend that the full agency approve aducanumab.
If the drug were approved, it would be the first new Alzheimer’s drug in nearly two decades. It would also be a remarkable reversal of fortunes for Biogen, which specializes in medicines to treat neurological conditions.
Read the full story.
|
|
|
|
|
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list.
|
|
|
|
